Styrax Capital LP Invests $28.76 Million in Guardant Health, Inc. $GH

Styrax Capital LP acquired a new position in Guardant Health, Inc. (NASDAQ:GH) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 281,589 shares of the company’s stock, valued at approximately $28,762,000. Guardant Health comprises 2.2% of Styrax Capital LP’s portfolio, making the stock its 15th biggest position. Styrax Capital LP owned 0.22% of Guardant Health at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Guardant Health by 13.4% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 10,187 shares of the company’s stock worth $1,040,000 after acquiring an additional 1,207 shares during the last quarter. Mariner LLC lifted its holdings in shares of Guardant Health by 43.1% in the 4th quarter. Mariner LLC now owns 5,611 shares of the company’s stock worth $572,000 after acquiring an additional 1,690 shares during the last quarter. Maven Securities LTD bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $2,554,000. Next Century Growth Investors LLC bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $1,888,000. Finally, First Turn Management LLC bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $27,750,000. 92.60% of the stock is currently owned by institutional investors.

Insider Activity at Guardant Health

In other news, CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the transaction, the chief executive officer owned 2,012,919 shares in the company, valued at $254,231,669.70. This trade represents a 4.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Steve E. Krognes sold 9,294 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $132.51, for a total value of $1,231,547.94. Following the transaction, the director owned 10,222 shares in the company, valued at $1,354,517.22. This trade represents a 47.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 449,006 shares of company stock worth $51,148,938 in the last ninety days. 5.60% of the stock is currently owned by company insiders.

Guardant Health Trading Down 1.9%

Shares of NASDAQ GH opened at $127.34 on Wednesday. The firm has a fifty day simple moving average of $104.90 and a two-hundred day simple moving average of $102.36. The firm has a market capitalization of $16.89 billion, a PE ratio of -37.56 and a beta of 1.61. Guardant Health, Inc. has a 12 month low of $40.35 and a 12 month high of $135.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on GH shares. TD Cowen restated a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. Raymond James Financial reiterated an “outperform” rating and set a $129.00 price target on shares of Guardant Health in a report on Monday, February 23rd. Piper Sandler set a $127.00 price target on shares of Guardant Health in a report on Thursday, May 21st. Wolfe Research began coverage on shares of Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target for the company. Finally, Evercore upgraded shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price target for the company in a report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $141.95.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.